{"entity":{"type":"insider","cik":"0001329161","url":"/insider/0001329161","json_url":"/insider/0001329161.json","name":"Adelman Robert J","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":61,"n_filings":33,"first":"2005-07-15","last":"2024-07-22","span_basis":"filed_date"},"name_variants":[{"name":"Adelman Robert J","source":"filing","n_filings":33,"first_seen":"2005-07-15","last_seen":"2024-07-22"}],"transactions":[{"id":2579334,"accession":"0000905148-24-001964","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000905148-24-001964","line_url":"/filing/0000905148-24-001964#line-4","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; GOODMAN COREY S; VENBIO GLOBAL STRATEGIC GP III, L.P.; VENBIO GLOBAL STRATEGIC GP III, LTD; venBio Global Strategic Fund III, L.P.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":416666.0,"shares_display":"416,666","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":4999992.0,"total_display":"4,999,992.00","total_whole":"4,999,992","shares_owned_after":1936637.0,"shares_owned_after_display":"1,936,637","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-22","filed_date":"2024-07-22","scope":"insider"},{"id":6915566,"accession":"0001140361-22-021085","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-22-021085","line_url":"/filing/0001140361-22-021085#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Elevation Oncology, Inc.","issuer_ticker":"ELEV","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; GOODMAN COREY S; Royston Aaron; VENBIO GLOBAL STRATEGIC GP III, L.P.; venBio Global Strategic Fund III, L.P.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":702737.0,"shares_display":"702,737","price_per_share":4.1236,"price_display":"4.12","price_state":"stated","total_value":2897806.2932,"total_display":"2,897,806.29","total_whole":"2,897,806","shares_owned_after":1905430.0,"shares_owned_after_display":"1,905,430","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-25","filed_date":"2022-05-27","scope":"insider"},{"id":6938420,"accession":"0001567619-22-011111","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-22-011111","line_url":"/filing/0001567619-22-011111#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic Fund II L.P.; GOODMAN COREY S; Adelman Robert J; venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.","owner_display_name":"venBio Global Strategic Fund II L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":95800.0,"shares_display":"95,800","price_per_share":10.4499,"price_display":"10.45","price_state":"stated","total_value":1001100.42,"total_display":"1,001,100.42","total_whole":"1,001,100","shares_owned_after":2155930.0,"shares_owned_after_display":"2,155,930","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-16","filed_date":"2022-05-17","scope":"insider"},{"id":6938416,"accession":"0001567619-22-011111","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-011111","line_url":"/filing/0001567619-22-011111#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic Fund II L.P.; GOODMAN COREY S; Adelman Robert J; venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.","owner_display_name":"venBio Global Strategic Fund II L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35850.0,"shares_display":"35,850","price_per_share":10.4453,"price_display":"10.45","price_state":"stated","total_value":374464.005,"total_display":"374,464.00","total_whole":"374,464","shares_owned_after":2251730.0,"shares_owned_after_display":"2,251,730","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-13","filed_date":"2022-05-17","scope":"insider"},{"id":6516288,"accession":"0001567619-22-010353","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-22-010353","line_url":"/filing/0001567619-22-010353#line-3","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"GOODMAN COREY S; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic Fund II L.P.; Adelman Robert J","owner_display_name":"GOODMAN COREY S","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":124525.0,"shares_display":"124,525","price_per_share":10.394,"price_display":"10.39","price_state":"stated","total_value":1294312.85,"total_display":"1,294,312.85","total_whole":"1,294,313","shares_owned_after":2287580.0,"shares_owned_after_display":"2,287,580","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-12","filed_date":"2022-05-12","scope":"insider"},{"id":6516286,"accession":"0001567619-22-010353","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-22-010353","line_url":"/filing/0001567619-22-010353#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"GOODMAN COREY S; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic Fund II L.P.; Adelman Robert J","owner_display_name":"GOODMAN COREY S","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17700.0,"shares_display":"17,700","price_per_share":10.3752,"price_display":"10.38","price_state":"stated","total_value":183641.04,"total_display":"183,641.04","total_whole":"183,641","shares_owned_after":2412105.0,"shares_owned_after_display":"2,412,105","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-11","filed_date":"2022-05-12","scope":"insider"},{"id":6516283,"accession":"0001567619-22-010353","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-010353","line_url":"/filing/0001567619-22-010353#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"GOODMAN COREY S; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic Fund II L.P.; Adelman Robert J","owner_display_name":"GOODMAN COREY S","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18676.0,"shares_display":"18,676","price_per_share":10.3807,"price_display":"10.38","price_state":"stated","total_value":193869.9532,"total_display":"193,869.95","total_whole":"193,870","shares_owned_after":2429805.0,"shares_owned_after_display":"2,429,805","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-10","filed_date":"2022-05-12","scope":"insider"},{"id":6280706,"accession":"0001567619-22-009850","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-22-009850","line_url":"/filing/0001567619-22-009850#line-3","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic Fund II L.P.; GOODMAN COREY S","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17600.0,"shares_display":"17,600","price_per_share":10.374,"price_display":"10.37","price_state":"stated","total_value":182582.4,"total_display":"182,582.40","total_whole":"182,582","shares_owned_after":2448481.0,"shares_owned_after_display":"2,448,481","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-09","filed_date":"2022-05-09","scope":"insider"},{"id":6280701,"accession":"0001567619-22-009850","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-22-009850","line_url":"/filing/0001567619-22-009850#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic Fund II L.P.; GOODMAN COREY S","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":48334.0,"shares_display":"48,334","price_per_share":10.3702,"price_display":"10.37","price_state":"stated","total_value":501233.2468,"total_display":"501,233.25","total_whole":"501,233","shares_owned_after":2466081.0,"shares_owned_after_display":"2,466,081","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-06","filed_date":"2022-05-09","scope":"insider"},{"id":6280697,"accession":"0001567619-22-009850","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-009850","line_url":"/filing/0001567619-22-009850#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic Fund II L.P.; GOODMAN COREY S","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20743.0,"shares_display":"20,743","price_per_share":10.37,"price_display":"10.37","price_state":"stated","total_value":215104.91,"total_display":"215,104.91","total_whole":"215,105","shares_owned_after":2514415.0,"shares_owned_after_display":"2,514,415","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-05","filed_date":"2022-05-09","scope":"insider"},{"id":6979290,"accession":"0001567619-22-009528","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-22-009528","line_url":"/filing/0001567619-22-009528#line-3","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic Fund II L.P.; GOODMAN COREY S","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37500.0,"shares_display":"37,500","price_per_share":10.3713,"price_display":"10.37","price_state":"stated","total_value":388923.75,"total_display":"388,923.75","total_whole":"388,924","shares_owned_after":2535158.0,"shares_owned_after_display":"2,535,158","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-04","filed_date":"2022-05-04","scope":"insider"},{"id":6979287,"accession":"0001567619-22-009528","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-22-009528","line_url":"/filing/0001567619-22-009528#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic Fund II L.P.; GOODMAN COREY S","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":79475.0,"shares_display":"79,475","price_per_share":10.3735,"price_display":"10.37","price_state":"stated","total_value":824433.9125,"total_display":"824,433.91","total_whole":"824,434","shares_owned_after":2572658.0,"shares_owned_after_display":"2,572,658","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-03","filed_date":"2022-05-04","scope":"insider"},{"id":6979284,"accession":"0001567619-22-009528","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-009528","line_url":"/filing/0001567619-22-009528#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic Fund II L.P.; GOODMAN COREY S","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":153700.0,"shares_display":"153,700","price_per_share":10.3837,"price_display":"10.38","price_state":"stated","total_value":1595974.69,"total_display":"1,595,974.69","total_whole":"1,595,975","shares_owned_after":2652133.0,"shares_owned_after_display":"2,652,133","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-02","filed_date":"2022-05-04","scope":"insider"},{"id":6579201,"accession":"0001567619-22-009203","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-22-009203","line_url":"/filing/0001567619-22-009203#line-3","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.; GOODMAN COREY S; Adelman Robert J; venBio Global Strategic Fund II L.P.","owner_display_name":"venBio Global Strategic GP II, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":69230.0,"shares_display":"69,230","price_per_share":10.3808,"price_display":"10.38","price_state":"stated","total_value":718662.784,"total_display":"718,662.78","total_whole":"718,663","shares_owned_after":2805833.0,"shares_owned_after_display":"2,805,833","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-29","filed_date":"2022-04-29","scope":"insider"},{"id":6579198,"accession":"0001567619-22-009203","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-22-009203","line_url":"/filing/0001567619-22-009203#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.; GOODMAN COREY S; Adelman Robert J; venBio Global Strategic Fund II L.P.","owner_display_name":"venBio Global Strategic GP II, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":73400.0,"shares_display":"73,400","price_per_share":10.3806,"price_display":"10.38","price_state":"stated","total_value":761936.04,"total_display":"761,936.04","total_whole":"761,936","shares_owned_after":2875063.0,"shares_owned_after_display":"2,875,063","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-28","filed_date":"2022-04-29","scope":"insider"},{"id":6579194,"accession":"0001567619-22-009203","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-009203","line_url":"/filing/0001567619-22-009203#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.; GOODMAN COREY S; Adelman Robert J; venBio Global Strategic Fund II L.P.","owner_display_name":"venBio Global Strategic GP II, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":47396.0,"shares_display":"47,396","price_per_share":10.3802,"price_display":"10.38","price_state":"stated","total_value":491979.9592,"total_display":"491,979.96","total_whole":"491,980","shares_owned_after":2948463.0,"shares_owned_after_display":"2,948,463","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-27","filed_date":"2022-04-29","scope":"insider"},{"id":6376270,"accession":"0001567619-22-008985","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-22-008985","line_url":"/filing/0001567619-22-008985#line-3","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic GP II, L.P.; Adelman Robert J; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, Ltd.; GOODMAN COREY S","owner_display_name":"venBio Global Strategic GP II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":64683.0,"shares_display":"64,683","price_per_share":10.3823,"price_display":"10.38","price_state":"stated","total_value":671558.3109,"total_display":"671,558.31","total_whole":"671,558","shares_owned_after":2995859.0,"shares_owned_after_display":"2,995,859","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-26","filed_date":"2022-04-26","scope":"insider"},{"id":6376267,"accession":"0001567619-22-008985","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-22-008985","line_url":"/filing/0001567619-22-008985#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic GP II, L.P.; Adelman Robert J; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, Ltd.; GOODMAN COREY S","owner_display_name":"venBio Global Strategic GP II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27668.0,"shares_display":"27,668","price_per_share":10.3876,"price_display":"10.39","price_state":"stated","total_value":287404.1168,"total_display":"287,404.12","total_whole":"287,404","shares_owned_after":3060542.0,"shares_owned_after_display":"3,060,542","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-25","filed_date":"2022-04-26","scope":"insider"},{"id":6376263,"accession":"0001567619-22-008985","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-008985","line_url":"/filing/0001567619-22-008985#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic GP II, L.P.; Adelman Robert J; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, Ltd.; GOODMAN COREY S","owner_display_name":"venBio Global Strategic GP II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37430.0,"shares_display":"37,430","price_per_share":10.3883,"price_display":"10.39","price_state":"stated","total_value":388834.069,"total_display":"388,834.07","total_whole":"388,834","shares_owned_after":3088210.0,"shares_owned_after_display":"3,088,210","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-22","filed_date":"2022-04-26","scope":"insider"},{"id":6579174,"accession":"0001567619-22-008823","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-22-008823","line_url":"/filing/0001567619-22-008823#line-3","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; Adelman Robert J; venBio Global Strategic Fund II L.P.; GOODMAN COREY S","owner_display_name":"venBio Global Strategic GP II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":62200.0,"shares_display":"62,200","price_per_share":10.3837,"price_display":"10.38","price_state":"stated","total_value":645866.14,"total_display":"645,866.14","total_whole":"645,866","shares_owned_after":3125640.0,"shares_owned_after_display":"3,125,640","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-21","filed_date":"2022-04-21","scope":"insider"},{"id":6579171,"accession":"0001567619-22-008823","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-22-008823","line_url":"/filing/0001567619-22-008823#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; Adelman Robert J; venBio Global Strategic Fund II L.P.; GOODMAN COREY S","owner_display_name":"venBio Global Strategic GP II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":85611.0,"shares_display":"85,611","price_per_share":10.3887,"price_display":"10.39","price_state":"stated","total_value":889386.9957,"total_display":"889,387.00","total_whole":"889,387","shares_owned_after":3187840.0,"shares_owned_after_display":"3,187,840","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-20","filed_date":"2022-04-21","scope":"insider"},{"id":6579169,"accession":"0001567619-22-008823","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-008823","line_url":"/filing/0001567619-22-008823#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; Adelman Robert J; venBio Global Strategic Fund II L.P.; GOODMAN COREY S","owner_display_name":"venBio Global Strategic GP II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":399923.0,"shares_display":"399,923","price_per_share":10.4151,"price_display":"10.42","price_state":"stated","total_value":4165238.0373,"total_display":"4,165,238.04","total_whole":"4,165,238","shares_owned_after":3273451.0,"shares_owned_after_display":"3,273,451","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-19","filed_date":"2022-04-21","scope":"insider"},{"id":5471590,"accession":"0001567619-21-018677","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-21-018677","line_url":"/filing/0001567619-21-018677#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Ventyx Biosciences, Inc.","issuer_ticker":"VTYX","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"VENBIO GLOBAL STRATEGIC GP III, LTD; venBio Global Strategic Fund III, L.P.; VENBIO GLOBAL STRATEGIC GP III, L.P.; GOODMAN COREY S; Adelman Robert J","owner_display_name":"VENBIO GLOBAL STRATEGIC GP III, LTD","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":312500.0,"shares_display":"312,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":3997269.0,"shares_owned_after_display":"3,997,269","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-25","filed_date":"2021-10-25","scope":"insider"},{"id":4327302,"accession":"0001567619-21-018722","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-21-018722","line_url":"/filing/0001567619-21-018722#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP, L.P.; venBio Global Strategic Fund, L.P.; venBio Global Strategic GP, Ltd.; GOODMAN COREY S","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":540667.0,"shares_display":"540,667","price_per_share":1.4907,"price_display":"1.49","price_state":"stated","total_value":805972.2969,"total_display":"805,972.30","total_whole":"805,972","shares_owned_after":2443421.0,"shares_owned_after_display":"2,443,421","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-25","filed_date":"2021-10-26","scope":"insider"},{"id":4327296,"accession":"0001567619-21-018722","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-21-018722","line_url":"/filing/0001567619-21-018722#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP, L.P.; venBio Global Strategic Fund, L.P.; venBio Global Strategic GP, Ltd.; GOODMAN COREY S","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":75035.0,"shares_display":"75,035","price_per_share":1.6383,"price_display":"1.64","price_state":"stated","total_value":122929.8405,"total_display":"122,929.84","total_whole":"122,930","shares_owned_after":2984088.0,"shares_owned_after_display":"2,984,088","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-22","filed_date":"2021-10-26","scope":"insider"},{"id":4187339,"accession":"0001567619-21-012858","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-21-012858","line_url":"/filing/0001567619-21-012858#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Elevation Oncology, Inc.","issuer_ticker":"ELEV","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic Fund III, L.P.; Royston Aaron; VENBIO GLOBAL STRATEGIC GP III, L.P.; Adelman Robert J; GOODMAN COREY S","owner_display_name":"venBio Global Strategic Fund III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":625000.0,"shares_display":"625,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":2608167.0,"shares_owned_after_display":"2,608,167","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-29","filed_date":"2021-07-01","scope":"insider"},{"id":4358016,"accession":"0000905148-21-000408","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000905148-21-000408","line_url":"/filing/0000905148-21-000408#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"IMPEL NEUROPHARMA INC","issuer_ticker":"IMPL","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; GOODMAN COREY S; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":450000.0,"shares_display":"450,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":6750000.0,"total_display":"6,750,000.00","total_whole":"6,750,000","shares_owned_after":2759791.0,"shares_owned_after_display":"2,759,791","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-27","filed_date":"2021-04-29","scope":"insider"},{"id":2420007,"accession":"0000905148-20-001038","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000905148-20-001038","line_url":"/filing/0000905148-20-001038#line-2","is_derivative":false,"issuer_cik":"0001329161","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001329161","owner_cik":"0001329161","owner_name":"Adelman Robert J","owner_display_name":"Adelman Robert J","owner_url":"/insider/0001329161","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":230000.0,"shares_display":"230,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":2990000.0,"total_display":"2,990,000.00","total_whole":"2,990,000","shares_owned_after":230000.0,"shares_owned_after_display":"230,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-18","filed_date":"2020-09-22","scope":"insider"},{"id":2170048,"accession":"0000905148-20-000880","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000905148-20-000880","line_url":"/filing/0000905148-20-000880#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Checkmate Pharmaceuticals, Inc.","issuer_ticker":"CMPI","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; GOODMAN COREY S; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","total_whole":"3,000,000","shares_owned_after":3673374.0,"shares_owned_after_display":"3,673,374","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-11","filed_date":"2020-08-12","scope":"insider"},{"id":3168100,"accession":"0000905148-20-000827","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000905148-20-000827","line_url":"/filing/0000905148-20-000827","is_derivative":false,"issuer_cik":"0001329161","issuer_name":"ALX ONCOLOGY HOLDINGS INC","issuer_ticker":"ALXO","issuer_name_source":null,"issuer_url":"/issuer/0001329161","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic Fund II L.P.; venBio Global Strategic Fund, L.P.; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP, L.P.; venBio Global Strategic GP, Ltd.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":853000.0,"shares_display":"853,000","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":16207000.0,"total_display":"16,207,000.00","total_whole":"16,207,000","shares_owned_after":5268325.0,"shares_owned_after_display":"5,268,325","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-21","filed_date":"2020-07-21","scope":"insider","n_lines":2},{"id":2134125,"accession":"0000905148-20-000773","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000905148-20-000773","line_url":"/filing/0000905148-20-000773#line-3","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; GOODMAN COREY S; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4603.0,"shares_display":"4,603","price_per_share":33.8304,"price_display":"33.83","price_state":"stated","total_value":155721.3312,"total_display":"155,721.33","total_whole":"155,721","shares_owned_after":3033552.0,"shares_owned_after_display":"3,033,552","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-06","filed_date":"2020-07-06","scope":"insider"},{"id":2134121,"accession":"0000905148-20-000773","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000905148-20-000773","line_url":"/filing/0000905148-20-000773#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; GOODMAN COREY S; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3800.0,"shares_display":"3,800","price_per_share":33.633,"price_display":"33.63","price_state":"stated","total_value":127805.4,"total_display":"127,805.40","total_whole":"127,805","shares_owned_after":3038155.0,"shares_owned_after_display":"3,038,155","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-02","filed_date":"2020-07-06","scope":"insider"},{"id":2134118,"accession":"0000905148-20-000773","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000905148-20-000773","line_url":"/filing/0000905148-20-000773#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; GOODMAN COREY S; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":108064.0,"shares_display":"108,064","price_per_share":34.4519,"price_display":"34.45","price_state":"stated","total_value":3723010.1216,"total_display":"3,723,010.12","total_whole":"3,723,010","shares_owned_after":3041955.0,"shares_owned_after_display":"3,041,955","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-01","filed_date":"2020-07-06","scope":"insider"},{"id":2210933,"accession":"0001012975-20-000291","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001012975-20-000291","line_url":"/filing/0001012975-20-000291#line-3","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"GOODMAN COREY S; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.; Adelman Robert J","owner_display_name":"GOODMAN COREY S","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1800.0,"shares_display":"1,800","price_per_share":23.7949,"price_display":"23.79","price_state":"stated","total_value":42830.82,"total_display":"42,830.82","total_whole":"42,831","shares_owned_after":3150019.0,"shares_owned_after_display":"3,150,019","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-06","filed_date":"2020-03-06","scope":"insider"},{"id":2210928,"accession":"0001012975-20-000291","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-20-000291","line_url":"/filing/0001012975-20-000291#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"GOODMAN COREY S; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.; Adelman Robert J","owner_display_name":"GOODMAN COREY S","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8500.0,"shares_display":"8,500","price_per_share":23.5307,"price_display":"23.53","price_state":"stated","total_value":200010.95,"total_display":"200,010.95","total_whole":"200,011","shares_owned_after":3151819.0,"shares_owned_after_display":"3,151,819","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-05","filed_date":"2020-03-06","scope":"insider"},{"id":2210878,"accession":"0001012975-20-000291","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-20-000291","line_url":"/filing/0001012975-20-000291#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"GOODMAN COREY S; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.; Adelman Robert J","owner_display_name":"GOODMAN COREY S","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35650.0,"shares_display":"35,650","price_per_share":23.8083,"price_display":"23.81","price_state":"stated","total_value":848765.895,"total_display":"848,765.90","total_whole":"848,766","shares_owned_after":3160319.0,"shares_owned_after_display":"3,160,319","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-04","filed_date":"2020-03-06","scope":"insider"},{"id":2171395,"accession":"0001012975-20-000275","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001012975-20-000275","line_url":"/filing/0001012975-20-000275#line-3","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"GOODMAN COREY S; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; Adelman Robert J","owner_display_name":"GOODMAN COREY S","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6401.0,"shares_display":"6,401","price_per_share":22.9962,"price_display":"23.00","price_state":"stated","total_value":147198.6762,"total_display":"147,198.68","total_whole":"147,199","shares_owned_after":3195969.0,"shares_owned_after_display":"3,195,969","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-03","filed_date":"2020-03-03","scope":"insider"},{"id":2171393,"accession":"0001012975-20-000275","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-20-000275","line_url":"/filing/0001012975-20-000275#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"GOODMAN COREY S; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; Adelman Robert J","owner_display_name":"GOODMAN COREY S","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10297.0,"shares_display":"10,297","price_per_share":23.061,"price_display":"23.06","price_state":"stated","total_value":237459.117,"total_display":"237,459.12","total_whole":"237,459","shares_owned_after":3202370.0,"shares_owned_after_display":"3,202,370","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-02","filed_date":"2020-03-03","scope":"insider"},{"id":2171390,"accession":"0001012975-20-000275","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-20-000275","line_url":"/filing/0001012975-20-000275#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"GOODMAN COREY S; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; Adelman Robert J","owner_display_name":"GOODMAN COREY S","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5100.0,"shares_display":"5,100","price_per_share":21.3044,"price_display":"21.30","price_state":"stated","total_value":108652.44,"total_display":"108,652.44","total_whole":"108,652","shares_owned_after":3212667.0,"shares_owned_after_display":"3,212,667","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-28","filed_date":"2020-03-03","scope":"insider"},{"id":2046900,"accession":"0001012975-20-000267","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001012975-20-000267","line_url":"/filing/0001012975-20-000267#line-3","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.; GOODMAN COREY S; venBio Global Strategic Fund II L.P.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1781.0,"shares_display":"1,781","price_per_share":22.54,"price_display":"22.54","price_state":"stated","total_value":40143.74,"total_display":"40,143.74","total_whole":"40,144","shares_owned_after":3227767.0,"shares_owned_after_display":"3,227,767","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-27","filed_date":"2020-02-27","scope":"insider"},{"id":2046899,"accession":"0001012975-20-000267","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-20-000267","line_url":"/filing/0001012975-20-000267#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.; GOODMAN COREY S; venBio Global Strategic Fund II L.P.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2523.0,"shares_display":"2,523","price_per_share":22.4397,"price_display":"22.44","price_state":"stated","total_value":56615.3631,"total_display":"56,615.36","total_whole":"56,615","shares_owned_after":3229548.0,"shares_owned_after_display":"3,229,548","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-26","filed_date":"2020-02-27","scope":"insider"},{"id":2046891,"accession":"0001012975-20-000267","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-20-000267","line_url":"/filing/0001012975-20-000267#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.; GOODMAN COREY S; venBio Global Strategic Fund II L.P.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1600.0,"shares_display":"1,600","price_per_share":23.6725,"price_display":"23.67","price_state":"stated","total_value":37876.0,"total_display":"37,876.00","total_whole":"37,876","shares_owned_after":3232071.0,"shares_owned_after_display":"3,232,071","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-25","filed_date":"2020-02-27","scope":"insider"},{"id":2603853,"accession":"0001012975-20-000119","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001012975-20-000119","line_url":"/filing/0001012975-20-000119#line-3","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic GP II, L.P.; Adelman Robert J; GOODMAN COREY S; venBio Global Strategic GP II, Ltd.; venBio Global Strategic Fund II L.P.","owner_display_name":"venBio Global Strategic GP II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6.0,"shares_display":"6","price_per_share":27.14,"price_display":"27.14","price_state":"stated","total_value":162.84,"total_display":"162.84","total_whole":"163","shares_owned_after":3233671.0,"shares_owned_after_display":"3,233,671","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-12","filed_date":"2020-02-12","scope":"insider"},{"id":2603850,"accession":"0001012975-20-000119","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-20-000119","line_url":"/filing/0001012975-20-000119#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic GP II, L.P.; Adelman Robert J; GOODMAN COREY S; venBio Global Strategic GP II, Ltd.; venBio Global Strategic Fund II L.P.","owner_display_name":"venBio Global Strategic GP II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2184.0,"shares_display":"2,184","price_per_share":27.0458,"price_display":"27.05","price_state":"stated","total_value":59068.0272,"total_display":"59,068.03","total_whole":"59,068","shares_owned_after":3233677.0,"shares_owned_after_display":"3,233,677","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-11","filed_date":"2020-02-12","scope":"insider"},{"id":2603846,"accession":"0001012975-20-000119","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-20-000119","line_url":"/filing/0001012975-20-000119#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"venBio Global Strategic GP II, L.P.; Adelman Robert J; GOODMAN COREY S; venBio Global Strategic GP II, Ltd.; venBio Global Strategic Fund II L.P.","owner_display_name":"venBio Global Strategic GP II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7836.0,"shares_display":"7,836","price_per_share":27.0761,"price_display":"27.08","price_state":"stated","total_value":212168.3196,"total_display":"212,168.32","total_whole":"212,168","shares_owned_after":3225861.0,"shares_owned_after_display":"3,225,861","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-10","filed_date":"2020-02-12","scope":"insider"},{"id":3241745,"accession":"0001012975-20-000115","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-20-000115","line_url":"/filing/0001012975-20-000115#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"GOODMAN COREY S; Adelman Robert J; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.","owner_display_name":"GOODMAN COREY S","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6102.0,"shares_display":"6,102","price_per_share":27.0329,"price_display":"27.03","price_state":"stated","total_value":164954.7558,"total_display":"164,954.76","total_whole":"164,955","shares_owned_after":3233697.0,"shares_owned_after_display":"3,233,697","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-06","filed_date":"2020-02-10","scope":"insider"},{"id":3322293,"accession":"0001012975-20-000113","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-20-000113","line_url":"/filing/0001012975-20-000113#line-2","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; GOODMAN COREY S; venBio Global Strategic Fund II L.P.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28608.0,"shares_display":"28,608","price_per_share":25.9909,"price_display":"25.99","price_state":"stated","total_value":743547.6672,"total_display":"743,547.67","total_whole":"743,548","shares_owned_after":3239799.0,"shares_owned_after_display":"3,239,799","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-05","filed_date":"2020-02-06","scope":"insider"},{"id":3322287,"accession":"0001012975-20-000113","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-20-000113","line_url":"/filing/0001012975-20-000113#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"Adelman Robert J; venBio Global Strategic GP II, L.P.; venBio Global Strategic GP II, Ltd.; GOODMAN COREY S; venBio Global Strategic Fund II L.P.","owner_display_name":"Adelman Robert J","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":53731.0,"shares_display":"53,731","price_per_share":25.6496,"price_display":"25.65","price_state":"stated","total_value":1378178.6576,"total_display":"1,378,178.66","total_whole":"1,378,179","shares_owned_after":3268407.0,"shares_owned_after_display":"3,268,407","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-04","filed_date":"2020-02-06","scope":"insider"},{"id":2068731,"accession":"0001012975-20-000033","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-20-000033","line_url":"/filing/0001012975-20-000033#line-1","is_derivative":false,"issuer_cik":"0001278411","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001278411","owner_cik":null,"owner_name":"GOODMAN COREY S; venBio Global Strategic Fund II L.P.; venBio Global Strategic GP II, Ltd.; venBio Global Strategic GP II, L.P.; Adelman Robert J","owner_display_name":"GOODMAN COREY S","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":494000.0,"shares_display":"494,000","price_per_share":20.23,"price_display":"20.23","price_state":"stated","total_value":9993620.0,"total_display":"9,993,620.00","total_whole":"9,993,620","shares_owned_after":3322138.0,"shares_owned_after_display":"3,322,138","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-01-13","filed_date":"2020-01-14","scope":"insider"}],"collapsed":true,"next_cursor":"2020-01-13|2068731","ledger_fault":false,"count":{"value":4,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":4,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":4},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001817241","name":"Artiva Biotherapeutics, Inc.","url":"/issuer/0001817241","role":"Ten percent owner","n_filings":1,"first_seen":"2024-07-22","last_seen":"2024-07-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001783032","name":"Elevation Oncology, Inc.","url":"/issuer/0001783032","role":"Ten percent owner","n_filings":2,"first_seen":"2021-07-01","last_seen":"2022-05-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001651431","name":"Checkmate Pharmaceuticals, Inc.","url":"/issuer/0001651431","role":"Ten percent owner","n_filings":8,"first_seen":"2020-08-12","last_seen":"2022-05-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001634379","name":"Metacrine, Inc.","url":"/issuer/0001634379","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2020-09-22","last_seen":"2021-10-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001851194","name":"Ventyx Biosciences, Inc.","url":"/issuer/0001851194","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2021-10-25","last_seen":"2021-10-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001445499","name":"IMPEL NEUROPHARMA INC","url":"/issuer/0001445499","role":"Ten percent owner","n_filings":1,"first_seen":"2021-04-29","last_seen":"2021-04-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001810182","name":"ALX ONCOLOGY HOLDINGS INC","url":"/issuer/0001810182","role":"Ten percent owner, Other","n_filings":1,"first_seen":"2020-07-21","last_seen":"2020-07-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001744659","name":"Akero Therapeutics, Inc.","url":"/issuer/0001744659","role":"Ten percent owner","n_filings":13,"first_seen":"2019-06-25","last_seen":"2020-07-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001357874","name":"PRECISION BIOSCIENCES INC","url":"/issuer/0001357874","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2019-04-01","last_seen":"2019-04-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001410064","name":"ARYx Therapeutics, Inc.","url":"/issuer/0001410064","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2007-11-14","last_seen":"2008-11-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001125294","name":"CRYOCOR INC","url":"/issuer/0001125294","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2005-07-15","last_seen":"2005-07-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001329161","retrieved_at":"2026-08-22T12:30:05+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}